Soligenix enters q4 with multiple catalysts in play

New york, new york--(newsfile corp. - october 13, 2022) - pcg digital -- late-stage biopharmaceutical company, soligenix, inc. (nasdaq: sngx) is anticipating significant catalysts in q4 and a potentially transformational year in 2023.following its successful phase 3 clinical trial evaluating hybryte (synthetic hypericin) as a treatment for cutaneous t-cell lymphoma (ctcl), soligenix is preparing to file a new drug application (nda) with the fda.
SNGX Ratings Summary
SNGX Quant Ranking